A lack of evidence is behind the NHS' decision to withhold a breakthrough prostate cancer drug from patients who have already been treated using another new generation drug, Nice said.
A spokeswoman for Nice said the committee were unable to "draw any conclusions" about what would happen if "milestone" enzalutamide was used by prostate cancer sufferers who had also taken abiraterone.
In the trial data provided by the manufacturer of enzalutamide none of the patients had received previous treatment with abiraterone, therefore the committee was not able to draw any conclusions about the effectiveness of enzalutamide after previous abiraterone treatment, and this is reflected in the recommendations.
We would welcome any additional data the manufacturer of enzalutamide can provide.
More top news
Scientists believe 400,000 cases of womb cancer have been avoided over the last 50 years by women taking the contraceptive pill.
Tony Blair could be made to stand trial for war crimes over the invasion of Iraq, Labour leadership frontrunner Jeremy Corbyn has said.
The number of fines handed out to hauliers found carrying illegal immigrants into the UK has more than tripled in the last three years.